Table 2.

Characteristics of de novo donor specific antibodies detected in pediatric patients after kidney transplant, by clinical stability at time of dnDSA detection.

	dnDSA detected on screening n=20	dnDSA detected on for-cause testing n=13
≥6 DSA tests in 2 years of monitoring	17 (85%)	10 (77%)
Time to DSA (days) (median(IQR))	332 (87–738)	543 (394–630)
Class of Initial DSA (n(%))
Class I	2 (10%)	2 (15%)
Class II	16 (80%)	7 (54%)
Class I & Class II	2 (10%)	4 (31%)
Initial DSA MFI (median(IQR))	2500 (1050–4350)	2400 (1300–3400)
Class of DSA overall (n(%))
Class I	2 (10%)	2 (15.4%)
Class II	13 (65%)	7 (15%)
Class I & Class II	5 (25%)	4 (31%)
Peak MFI overall (median(IQR))	6150 (2750–11600)	4100 (2200–8900)
C1q positive (n(%))	6 (43%)	2 (40%)
Biopsy within 3 months of positive DSA	10 (50%)	10 (77%)
Antibody-mediated rejection	1 (10%)	1 (10%)
Acute cellular rejection	3 (30%)	6 (60%)
Duration of DSA (days) (median(IQR))	378 (85–596)	172 (85–241)
DSA resolved before 2 years (n(%))	6 (30%)	4 (31%)
CV for tacrolimus trough level (mean(sd))	34.9% (12.5)	35.3% (12.4)

CV: coefficient of variation